You are here

  • Home
  • Archive
  • Volume 74, Issue Suppl 2
  • AB0488 Influences of 2-Year Tocilizumab Therapy on Disease Activity, Quality of Life, Prevention of Joint Damage and Reduction of Concomitant Drugs (Prednisolone and Methotrexate) in Patients with Rheumatoid Arthritis

Citation Tools

Article menu
Download PDFPDF
Abstracts Accepted for Publication
Rheumatoid arthritis - other biologic treatment
AB0488 Influences of 2-Year Tocilizumab Therapy on Disease Activity, Quality of Life, Prevention of Joint Damage and Reduction of Concomitant Drugs (Prednisolone and Methotrexate) in Patients with Rheumatoid Arthritis

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Hirano Y, Hirabara S, Isono M, et al
AB0488 Influences of 2-Year Tocilizumab Therapy on Disease Activity, Quality of Life, Prevention of Joint Damage and Reduction of Concomitant Drugs (Prednisolone and Methotrexate) in Patients with Rheumatoid Arthritis
Annals of the Rheumatic Diseases 2015;74:1061.